3D ANNOUNCES PRIVATE PLACEMENT WITH STRATEGIC PARTNER 3D Signatures arranges $500K financing with ScreenCell
3D Signatures Inc (C:DXD)
Shares Issued 46,445,199
Last Close 10/3/2017 $0.25
Tuesday October 3, 2017 - News Release
Mr. Jason Flowerday reports
3D SIGNATURES ANNOUNCES PRIVATE PLACEMENT WITH STRATEGIC PARTNER AND PROSPECTUS UPDATE
3D Signatures Inc. has arranged a non-brokered private placement of two million common shares at a price of 25 cents per share for gross proceeds of $500,000 with ScreenCell SA.
ScreenCell, a strategic partner to 3DS, has been working closely with the Company since its inception and has a deep working knowledge of 3DS' technology. ScreenCell supplies the Company with a screening system for the capture and isolation of circulating tumor cells ("CTCs") from blood.
"It's a strong endorsement of 3DS when a major supplier and technology collaborator makes a financial investment in the Company," stated Jason Flowerday, 3DS' CEO. "ScreenCell is a leader in its field and we look forward to a continued partnership."
The Private Placement is subject to receipt of all necessary regulatory and stock exchange approval, including the approval of the TSX Venture Exchange. The Shares issued pursuant to the Private Placement will be subject to a four-month hold period in accordance with applicable Canadian securities law.
The use of proceeds of the Private Placement is for clinical operations, namely the Company's Hodgkin's lymphoma clinical trial, including clinical wages and laboratory expenses, and general working capital.
In addition to the Private Placement, the Company intends to file an amended and restated preliminary short form prospectus as soon as possible in relation to the offering first announced by the Company on July 19, 2017, in order to incorporate amendments related to the closing of the Private Placement and to update other relevant information.
About 3DS
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company's website at https://www.3dsignatures.com.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd.